Clinical Trials

Multiple Myeloma

NCT06158841 2026-05-27

CERVINO

380 enrolled

Multiple Myeloma

NCT07555938 2026-05-27

CEVOLUTION

380 enrolled

Multiple Myeloma

NCT07227311 2026-05-26

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Phase 2 Recruiting

200 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

74 enrolled

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT04933539 2026-05-22

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

14 enrolled

Multiple Myeloma

NCT06152575 2026-05-22

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03104842 2026-05-15

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

246 enrolled

Multiple Myeloma

NCT07082270 2026-05-15

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT07479979 2026-05-14

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT05497804 2026-05-13

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT06615479 2026-05-13

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma, Recurrence

NCT06948084 2026-05-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

80 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07463807 2026-05-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

162 enrolled

Multiple Myeloma

NCT04263480 2026-05-12

CZAR-1

99 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Neoplasms

NCT03934684 2026-05-11

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Phase 4 Completed

101 enrolled 14 charts

Multiple Myeloma

NCT04973605 2026-05-11

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Multiple Myeloma

NCT05060627 2026-05-11

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

60 enrolled

Multiple Myeloma

NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT05050097 2026-05-08

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT05438043 2026-05-08

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT06413498 2026-05-07

iMMagine-3

450 enrolled

Multiple Myeloma

NCT03556332 2026-05-05

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

41 enrolled

Multiple Myeloma

NCT02343042 2026-05-04

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT07391657 2026-04-30

DURGA-4

508 enrolled

Multiple Myeloma

NCT01816971 2026-04-21

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

76 enrolled 12 charts

Multiple Myeloma

NCT06622005 2026-04-21

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

15 enrolled

Multiple Myeloma

NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

70 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05434689 2026-04-15

COMMANDER

80 enrolled

Multiple Myeloma

NCT02203643 2026-04-14

FORTE

477 enrolled

Multiple Myeloma

NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

75 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT05675449 2026-04-13

MagnetisMM-20

59 enrolled

Multiple Myeloma, Recurrence

NCT02405364 2026-04-08

IFM-CRd

46 enrolled

Multiple Myeloma

NCT02302495 2026-04-07

IFM2012-03

32 enrolled

Multiple Myeloma

NCT01813227 2026-04-03

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

7 enrolled 10 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT06249282 2026-04-03

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Recruiting

15 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05552976 2026-04-01

SUCCESSOR-2

606 enrolled

Multiple Myeloma, Recurrence

NCT04268498 2026-03-24

ADVANCE

310 enrolled

Multiple Myeloma

NCT01297764 2026-03-23

QUAD

17 enrolled

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

30 enrolled

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

Phase 2 Recruiting

30 enrolled

Multiple Myeloma

NCT01572480 2026-03-10

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

55 enrolled 17 charts

Multiple Myeloma

NCT02659293 2026-03-04

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

180 enrolled

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

250 enrolled

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Multiple Myeloma

NCT03909412 2026-02-18

CarMob

Phase 1 Recruiting

18 enrolled

Multiple Myeloma

NCT05199311 2026-02-18

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

66 enrolled

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled